Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 1, 2017 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate the post-hematopoietic (stem) cell transplant outcomes for older patients with AML in their second complete remission.

This study concluded that hematopoietic cell transplant is a good treatment option, especially for patients with favorable- or intermediate-cytogenetic risk status. 

Some background

Acute myeloid leukemia (AML) occurs when abnormal myeloblasts are produced. Myeloblasts are a type of white blood cell that produce other cells. Abnormal myeloblasts cannot produce healthy cells. Lack of healthy cells can lead to a weak immune system, infection and bleeding.

An allogenic hematopoietic cell transplant (HCT) is a potential cure for older patients with AML in their first complete remission (no signs of cancer). It involves taking stem cells from a donor and putting them into the AML patient. Stem cells can produce any cell type and help to restore the immune system.

Cytogenetic-risk status is different for each patient and is thought to be a factor that can influence treatment outcomes.  

It was not known what the outcomes for older patients in their second complete remission would be post-HCT and what influence cytogenetic-risk status would have. 

Methods & findings

The aim of this study was to look at factors that influence the post-HCT outcomes in the second complete remission. This study involved 196 patients aged 60 and older who underwent HCT for AML in their second complete remission. 81% received reduced-intensity conditioning (chemotherapy) before HCT.

The three-year overall survival (OS, time from treatment until death from any cause) rate for patients who underwent HCT was 42%. The three-year leukemia-free survival rate for patients who underwent HCT was 37%.

The non-relapse mortality rate (death due to causes other than AML returning) for patients who underwent HCT was 25%. The relapse rate (cancer returns) was 38%.

Cytogenetic risk was the only factor that influenced OS. Patients with intermediate-risk cytogenetics were 14% more likely to have reduced OS. Patients with unfavorable-risk cytogenetics were 2.32 times more likely to have reduced OS.

Cytogenetic risk was the only factor that influenced the relapse rate. Patients with intermediate-risk cytogenetics were 10% more likely to have an increased relapse rate. Patients with unfavorable-risk cytogenetics were almost 3 times more likely to have an increased relapse rate.

The bottom line

This study concluded that allogeneic HCT is a treatment option for older patients with AML in their second remission that may be curative. Patients with favorable- or intermediate-cytogenetic risk are more likely to benefit.  

The fine print

Larger studies need to be carried out. 

What’s next?

Consult your physician about HCT as a treatment option for AML.  

Published By :

Cancer

Date :

Jun 01, 2017

Original Title :

Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.

click here to get personalized updates